Bajaj Healthcare Limited announced strong Q3FY26 financial results with revenue from operations growing 31.3% year-on-year to ₹1,612.2 million, driven primarily by exceptional performance in API exports. The pharmaceutical manufacturer, specializing in APIs, intermediates and formulations, demonstrated robust operational momentum across key business segments for the quarter ended December 31, 2025.

Financial Performance Highlights

The company's financial metrics showed significant improvement across multiple parameters during Q3FY26:

EBITDA growth of 34.6% to ₹323.3 million outpaced revenue growth, with margins expanding to 19.8% from 19.2% in the corresponding quarter last year. Profit for the period surged 33.7% to ₹156.7 million, reflecting improved operational efficiency.

Segment-wise Revenue Performance

API exports emerged as the standout performer, driving overall revenue growth:

API exports more than doubled with growth of 109.8% to ₹486.8 million, demonstrating the company's expanding presence in international markets. Domestic API business maintained steady growth of 15.3% to ₹838.5 million, while formulations contributed ₹287.0 million with 6.8% growth.

Nine-Month Performance

For the nine months ended December 31, 2025, Bajaj Healthcare sustained strong momentum:

Nine-month revenue reached ₹4,579.7 million with 18.0% growth, while profit for the period increased 36.4% to ₹386.2 million, indicating sustained operational improvements throughout the fiscal year.

Key Business Developments

The company achieved several significant regulatory and product milestones during the quarter:

• Became the first Indian company to receive CDSCO approval for Phase III clinical trials and bioequivalence studies of Suvorexant Tablets
• Successfully launched Magnesium L-Threonate (Magtein) in India through collaboration with Threotech LLC
• Filed 9 Drug Master Files (DMFs) during the quarter, bringing cumulative DMF filings to 69
• Maintained ten cumulative CEP filings with eight approved and two under review

These developments strengthen the company's position in regulated markets and expand its CNS portfolio offerings.

Management Commentary

Managing Director Anil Jain highlighted the company's resilient performance amid global volatility, emphasizing the strong API export growth and expanding CDMO business. He noted the company's continued focus on CNS portfolio advancement with ongoing Phase III trials for Cenobamate and the recent Magtein launch, while maintaining emphasis on regulatory compliance and product registrations across key geographies for sustained growth in regulated markets.

Bajaj Healthcare Limited delivered exceptional financial performance in Q3, with net profit rising 34.20% year-on-year to ₹15.67 crores, compared with ₹11.72 crores in the corresponding quarter last year. The pharmaceutical company's board of directors approved the quarterly results on January 16, 2026, showcasing robust operational performance and improved margin efficiency.

Strong Revenue Growth Drives Q3 Performance

The company's quarterly performance demonstrated substantial improvement across multiple parameters, with revenue and profitability showing remarkable growth:

Revenue for the quarter increased 31.31% to ₹161.22 crores, up from ₹122.79 crores in Q3 of the previous financial year. The revenue surge was primarily driven by improved operational efficiency and market expansion. EBITDA grew at a faster pace of 42.13% to ₹30.70 crores, reflecting better cost control and operating leverage.

Margin Expansion Highlights Operational Efficiency

Operating margin expanded significantly to 19.03% from 17.62% year-on-year, indicating improved profitability despite ongoing cost pressures across the sector. The EBITDA margin improvement of 141 basis points reflects enhanced cost management and operational leverage. Total income for the quarter reached ₹162.87 crores compared to ₹125.17 crores in the corresponding quarter of the previous year.

Nine-Month Performance Shows Consistent Growth

For the nine-month period ended December 31, 2025, Bajaj Healthcare maintained its growth trajectory:

The nine-month results reflect sustained business momentum with revenue crossing ₹450 crores and net profit showing strong double-digit growth.

Leadership Continuity Through Executive Re-appointments

The board approved the re-appointment of four key executive directors for three-year terms:

All re-appointments are subject to shareholder approval through postal ballot. The leadership team brings decades of combined experience in pharmaceuticals, finance, marketing, and operations.

Market Performance and Business Outlook

Bajaj Healthcare shares closed at ₹389.30, down ₹4.85, or 1.23%, on January 16, 2026. The company operates primarily in the pharmaceuticals segment, dealing with formulations and active pharmaceutical ingredients. The strong Q3 performance underscores steady growth across key financial metrics, positioning the company well for the remainder of the financial year.